SMP200900099B - Composizione a rilascio protratto comprendente un derivato della somatostatina in microparticelle. - Google Patents

Composizione a rilascio protratto comprendente un derivato della somatostatina in microparticelle.

Info

Publication number
SMP200900099B
SMP200900099B SM200900099T SM200900099T SMP200900099B SM P200900099 B SMP200900099 B SM P200900099B SM 200900099 T SM200900099 T SM 200900099T SM 200900099 T SM200900099 T SM 200900099T SM P200900099 B SMP200900099 B SM P200900099B
Authority
SM
San Marino
Prior art keywords
microparticles
release composition
prolonged release
somatostatin derivative
somatostatin
Prior art date
Application number
SM200900099T
Other languages
English (en)
Other versions
SMAP200900099A (it
Inventor
Olivier Lambert
Marc Riemenschnitter
Vitomir Vucenovic
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38222465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMP200900099(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SMAP200900099A publication Critical patent/SMAP200900099A/it
Publication of SMP200900099B publication Critical patent/SMP200900099B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
SM200900099T 2007-05-24 2009-12-23 Composizione a rilascio protratto comprendente un derivato della somatostatina in microparticelle. SMP200900099B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07108796 2007-05-24
PCT/EP2008/056347 WO2008142153A1 (en) 2007-05-24 2008-05-23 An extended-release composition comprising a somatostatin derivative in microparticles

Publications (2)

Publication Number Publication Date
SMAP200900099A SMAP200900099A (it) 2010-01-19
SMP200900099B true SMP200900099B (it) 2010-11-12

Family

ID=38222465

Family Applications (1)

Application Number Title Priority Date Filing Date
SM200900099T SMP200900099B (it) 2007-05-24 2009-12-23 Composizione a rilascio protratto comprendente un derivato della somatostatina in microparticelle.

Country Status (42)

Country Link
US (2) US20100178344A1 (it)
EP (2) EP2164473B1 (it)
JP (1) JP5507447B2 (it)
KR (2) KR20100017904A (it)
CN (1) CN101677965B (it)
AR (1) AR066677A1 (it)
AU (1) AU2008252931B2 (it)
BR (1) BRPI0811904A2 (it)
CA (1) CA2683935C (it)
CL (1) CL2008001509A1 (it)
CO (1) CO6241097A2 (it)
CR (1) CR11078A (it)
CU (1) CU24028B1 (it)
DK (1) DK2164473T3 (it)
DO (1) DOP2009000262A (it)
EA (1) EA018203B1 (it)
EC (1) ECSP099793A (it)
ES (1) ES2761227T3 (it)
GE (1) GEP20125582B (it)
GT (1) GT200900302A (it)
HN (1) HN2009003296A (it)
HU (1) HUE046490T2 (it)
IL (1) IL201571B (it)
MA (1) MA31445B1 (it)
ME (1) ME00955B (it)
MX (1) MX2009012536A (it)
MY (1) MY148915A (it)
NI (1) NI200900207A (it)
NZ (1) NZ580589A (it)
PA (1) PA8781501A1 (it)
PE (1) PE20090387A1 (it)
PL (1) PL2164473T3 (it)
PT (1) PT2164473T (it)
SI (1) SI2164473T1 (it)
SM (1) SMP200900099B (it)
SV (1) SV2009003421A (it)
TN (1) TN2009000447A1 (it)
TW (1) TWI412373B (it)
UA (1) UA97396C2 (it)
UY (1) UY31103A1 (it)
WO (1) WO2008142153A1 (it)
ZA (1) ZA200907168B (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
US20120156304A1 (en) * 2010-12-15 2012-06-21 Thomas Tice Branched polyol polyesters, blends, and pharmaceutical formulations comprising same
PL3199146T3 (pl) 2011-04-25 2020-03-31 Shan Dong Luye Pharmaceutical Co., Ltd. Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiu
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AU2013265210B2 (en) * 2012-05-25 2016-09-15 Camurus Ab Somatostatin receptor agonist formulations
US10821200B2 (en) 2016-12-05 2020-11-03 Hyalo Technologies, LLC Method of sterilization of microparticles
EP3339372A1 (en) * 2016-12-22 2018-06-27 Solvay SA Glycolic acid polymer composition
CN110870853B (zh) * 2018-08-29 2020-12-11 深圳翰宇药业股份有限公司 缓释帕瑞肽微球及其制备方法
JP7532367B2 (ja) * 2018-12-04 2024-08-13 バンダ・ファーマシューティカルズ・インコーポレイテッド イロペリドンの持効性投与

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
CA2316052C (en) * 1989-07-07 2008-09-02 David Bodmer Sustained release formulations of water soluble peptides
FI106926B (fi) * 1989-07-07 2001-05-15 Novartis Ag Menetelmä pitkäaikaisesti vapautuvan koostumuksen muodostamiseksi
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
EP1240896A3 (en) 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
CA2546448A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Biomarkers for the efficacy of somatostatin analogue treatment

Also Published As

Publication number Publication date
AR066677A1 (es) 2009-09-02
EP2164473A1 (en) 2010-03-24
SV2009003421A (es) 2010-05-21
UA97396C2 (ru) 2012-02-10
SI2164473T1 (sl) 2020-02-28
ES2761227T3 (es) 2020-05-19
DOP2009000262A (es) 2010-10-15
GT200900302A (es) 2011-07-01
NI200900207A (es) 2010-09-07
PA8781501A1 (es) 2008-12-18
CR11078A (es) 2009-12-04
CN101677965A (zh) 2010-03-24
AU2008252931A1 (en) 2008-11-27
BRPI0811904A2 (pt) 2014-11-18
CO6241097A2 (es) 2011-01-20
US20100178344A1 (en) 2010-07-15
MA31445B1 (fr) 2010-06-01
PE20090387A1 (es) 2009-04-28
GEP20125582B (en) 2012-07-25
EA018203B1 (ru) 2013-06-28
CU24028B1 (es) 2014-10-02
US9351923B2 (en) 2016-05-31
TW200906437A (en) 2009-02-16
ECSP099793A (es) 2010-01-29
JP2010527971A (ja) 2010-08-19
PT2164473T (pt) 2019-12-11
CL2008001509A1 (es) 2009-05-08
US20130129798A1 (en) 2013-05-23
KR20100017904A (ko) 2010-02-16
CA2683935A1 (en) 2008-11-27
UY31103A1 (es) 2009-01-05
IL201571B (en) 2018-11-29
EP2164473B1 (en) 2019-09-11
MX2009012536A (es) 2009-12-03
TN2009000447A1 (en) 2011-03-31
EP3666263A1 (en) 2020-06-17
CN101677965B (zh) 2015-09-09
CU20090200A7 (es) 2011-09-21
HUE046490T2 (hu) 2020-03-30
EA200901523A1 (ru) 2010-04-30
IL201571A0 (en) 2010-05-31
KR101930588B1 (ko) 2018-12-18
SMAP200900099A (it) 2010-01-19
AU2008252931B2 (en) 2011-09-01
HN2009003296A (es) 2014-02-10
NZ580589A (en) 2011-12-22
MY148915A (en) 2013-06-14
ZA200907168B (en) 2010-07-28
ME00955B (me) 2012-06-20
WO2008142153A1 (en) 2008-11-27
KR20160002937A (ko) 2016-01-08
DK2164473T3 (da) 2019-12-16
PL2164473T3 (pl) 2020-07-27
JP5507447B2 (ja) 2014-05-28
CA2683935C (en) 2016-07-19
TWI412373B (zh) 2013-10-21

Similar Documents

Publication Publication Date Title
SMP200900099B (it) Composizione a rilascio protratto comprendente un derivato della somatostatina in microparticelle.
ATE513831T1 (de) Pyridinä3,4-büpyrazinone
ATE502012T1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivat
DK2051606T3 (da) Lænestol
DE502006006067D1 (de) Ng
ITMI20060591A1 (it) Innesto rapido
CY2200166T2 (el) Βελτιωμενη αγκυρωση ολισθησης
NO2015006I1 (no) Flutemetamol (18F)
DE112008000295A5 (de) Steckerstift
EP2145884A4 (en) INDOLEDIONDERIVAT
DK2134733T3 (da) Palladium(0)-dibenzylidenacetonekomplekser
FR2925235B1 (fr) Socle antivibratile multi-format
DE602007003045D1 (de) Anzeigetafel
ES1062273Y (es) Butaca perfeccionada
HK1145471A1 (en) Pin setter
DE502006002564D1 (de) Ndungen
DE112007001493A5 (de) Ordnermechanik
SE0600253L (sv) Hållaranordning
TH93137B (th) ของประดับตกแต่ง
TH92789B (th) ของประดับตกแต่ง
TH102818B (th) ของประดับตกแต่ง
TH92786B (th) ของประดับตกแต่ง
TH93138B (th) ของประดับตกแต่ง
TH92787B (th) ของประดับตกแต่ง
GB0610314D0 (en) Foot rotator